Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?

In 2005, we performed the largest survey on clinical trials of biotherapies for all solid tumors and found indirect evidence of a publication bias: editors of medical journals were more prone to publish positive results independently from the quality of the studies. We collected data from 2003 to 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Ottaiano, Alessandro, Cassata, Antonino, Capozzi, Monica, De Divitiis, Chiara, De Stefano, Alfonso, Avallone, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861183/
https://www.ncbi.nlm.nih.gov/pubmed/29594042
http://dx.doi.org/10.3389/fonc.2018.00062
_version_ 1783308051442302976
author Ottaiano, Alessandro
Cassata, Antonino
Capozzi, Monica
De Divitiis, Chiara
De Stefano, Alfonso
Avallone, Antonio
author_facet Ottaiano, Alessandro
Cassata, Antonino
Capozzi, Monica
De Divitiis, Chiara
De Stefano, Alfonso
Avallone, Antonio
author_sort Ottaiano, Alessandro
collection PubMed
description In 2005, we performed the largest survey on clinical trials of biotherapies for all solid tumors and found indirect evidence of a publication bias: editors of medical journals were more prone to publish positive results independently from the quality of the studies. We collected data from 2003 to 2015 in 487 studies, and the publication bias previously described was not found in the years between 2010 and 2015: this could be related to changes and/or innovations in the guidelines and editorial policies of oncology journals occurred over the last years.
format Online
Article
Text
id pubmed-5861183
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-58611832018-03-28 Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication? Ottaiano, Alessandro Cassata, Antonino Capozzi, Monica De Divitiis, Chiara De Stefano, Alfonso Avallone, Antonio Front Oncol Oncology In 2005, we performed the largest survey on clinical trials of biotherapies for all solid tumors and found indirect evidence of a publication bias: editors of medical journals were more prone to publish positive results independently from the quality of the studies. We collected data from 2003 to 2015 in 487 studies, and the publication bias previously described was not found in the years between 2010 and 2015: this could be related to changes and/or innovations in the guidelines and editorial policies of oncology journals occurred over the last years. Frontiers Media S.A. 2018-03-14 /pmc/articles/PMC5861183/ /pubmed/29594042 http://dx.doi.org/10.3389/fonc.2018.00062 Text en Copyright © 2018 Ottaiano, Cassata, Capozzi, De Divitiis, De Stefano and Avallone. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ottaiano, Alessandro
Cassata, Antonino
Capozzi, Monica
De Divitiis, Chiara
De Stefano, Alfonso
Avallone, Antonio
Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?
title Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?
title_full Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?
title_fullStr Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?
title_full_unstemmed Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?
title_short Biotherapies in Solid Tumors: Are Negative Results Still of Low Priority for Publication?
title_sort biotherapies in solid tumors: are negative results still of low priority for publication?
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861183/
https://www.ncbi.nlm.nih.gov/pubmed/29594042
http://dx.doi.org/10.3389/fonc.2018.00062
work_keys_str_mv AT ottaianoalessandro biotherapiesinsolidtumorsarenegativeresultsstilloflowpriorityforpublication
AT cassataantonino biotherapiesinsolidtumorsarenegativeresultsstilloflowpriorityforpublication
AT capozzimonica biotherapiesinsolidtumorsarenegativeresultsstilloflowpriorityforpublication
AT dedivitiischiara biotherapiesinsolidtumorsarenegativeresultsstilloflowpriorityforpublication
AT destefanoalfonso biotherapiesinsolidtumorsarenegativeresultsstilloflowpriorityforpublication
AT avalloneantonio biotherapiesinsolidtumorsarenegativeresultsstilloflowpriorityforpublication

Ejemplares similares